Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00706264

Recruitment Status : Completed

First Posted : June 27, 2008

Results First Posted : March 17, 2021

Last Update Posted : March 17, 2021

Sponsor:

Collaborators:

Hospital Universitario de Canarias

Hospital Son Llatzer

Institut Universitari Dexeus

Information provided by (Responsible Party):

Maria Goya, MD, PhD, Maternal-Infantil Vall d´Hebron Hospital

Study Description

Brief Summary:

Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length at 18-22 weeks scan.

Condition or disease	Intervention/treatment	Phase
Preterm Birth	Device: Silicon ring (Arabin Pessary)	Not Applicable

Detailed Description:

This trial includes pregnant women undergoing routine ultrasound examination at 18.0 to 22.6 weeks of gestation.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	385 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Outcomes Assessor)
Primary Purpose:	Prevention
Official Title:	Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)
Study Start Date :	June 2007
Actual Primary Completion Date :	July 2014
Actual Study Completion Date :	July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
No Intervention: 1 Expectant management
Experimental: 2 Placement of arabin pessary since 23 weeks until 37 weeks	Device: Silicon ring (Arabin Pessary) Placement of a silicon pessary in the vagina, around the cervix. Other Name: Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003

Outcome Measures

Primary Outcome Measures :

Spontaneous Delivery Before 34 Completed Weeks [ Time Frame: Between 24 and 34 weeks ]
Number of spontaneous preterm births before 34 weeks occurred in each group.

Secondary Outcome Measures :

Birthweight Less Than 1500 g [ Time Frame: Time of delivery ]
Number of newborns whose birthweight is less than 1500 grams
Birthweight Less Than 2500 g [ Time Frame: Time of delivery ]
Number of newborns whose birthweight is less than 2500 grams
Intrauterine Fetal Demise [ Time Frame: Pregnancy ]
The number of fetal deaths in the pessary group was compared to those in the no pessary group
Neonatal Death [ Time Frame: Between birth and 28 days of age ]
The number of neonatal deaths in the pessary group was compared to those in the no pessary group
Intraventricular Haemorrhage [ Time Frame: Between birth and 28 days of age ]
The number of neonatal intraventricular haemorrhage in the pessary group was compared to those in the no pessary group
Respiratory Distress Syndrome [ Time Frame: Between birth and 28 days of age ]
The number of neonatal Respiratory distress syndrome in the pessary group was compared to those in the no pessary group
Retinopathy of Prematurity [ Time Frame: Between birth and 28 days of age ]
The number of neonatal retinopathy in the pessary group was compared to those in the no pessary group
Necrotising Enterocolitis [ Time Frame: Between birth and 28 days of age ]
The number of neonatal necrotising enterocolitis in the pessary group was compared to those in the no pessary group
Treatment for Sepsis [ Time Frame: Between birth and 28 days of age ]
The number of neonatal cases of treatment needed for sepsis in the pessary group was compared to those in the no pessary group
Composite Adverse Outcomes [ Time Frame: Between birth and 28 days of age ]
The number of neonatal cases with composite adverse outcomes in the pessary group was compared to those in the no pessary group
Spontaneous Delivery Before 28 Completed Weeks [ Time Frame: Between 24 and 28 weeks ]
Number of preterm births before 28 weeks occurred in each group.
Any Delivery Before 34 Completed Weeks [ Time Frame: Between 24 and 34 weeks ]
Number of all preterm births before 34 weeks occurred in each group.
Spontaneous Delivery Before 37 Completed Weeks [ Time Frame: Between 24 and 37 weeks ]
Number of preterm births before 37 weeks occurred in each group.
Gestational Age at Delivery [ Time Frame: At time of birth ]
Number of weeks of gestation completed by time of delivery
Use of Tocolysis [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants required use of tocolytic medication
Use of Antenatal Steroids [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants that received betamethasone to reduce morbidity of expected preterm delivery
Chorioamnionitis [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants that showed intrauterine infection diagnosed by maternal tachycardia, fever, uterine tenderness, purulent or abnormal cervical discharge, fetal tachycardia.
Vaginal Bleeding [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants who experienced bleeding from lower genital tract during antepartum period
Preterm Premature Rupture of Membranes [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants who experienced rupture of membranes as diagnosed by speculum exam showing pooling, ferning, positive nitrazine test, positive amnisure test.
Cesarean Delivery [ Time Frame: At time of delivery ]
Number of participants that underwent cesarean delivery
Vaginal Discharge [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants who experienced an increased vaginal discharge.
Pessary Repositioning Without Removal [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants who required pessary repositioning without removal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).
Pessary Withdrawal [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]
Number of participants who experience pessary withdrawal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Singleton pregnancy
Minimal age of 18 years

Exclusion Criteria:

Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
SROM at the time of randomization
Cervical cerclage in situ
Active vaginal bleeding
Previous cone biopsy or cerclage
Major uterine structural anomalies
Placenta previa

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00706264

Locations

Layout table for location information

Spain
Hospital Materno-Infantil de Canarias
Las Palmas de Gran Canaria, Gran Canaria, Spain, 35016
Hospital Son Llàtzer
Palma de Mallorca, Mallorca, Spain, 07198
Hospital de Reus
Reus, Tarragona, Spain
Hospital Vall d´Hebron
Barcelona, Spain, 08035
Institut Universitary Dexeus
Barcelona, Spain
Hospital de Fuenlabrada
Madrid, Spain

Sponsors and Collaborators

Maternal-Infantil Vall d´Hebron Hospital

Hospital Universitario de Canarias

Hospital Son Llatzer

Institut Universitari Dexeus

Investigators

Layout table for investigator information

Study Director:	ELENA CARRERAS, PhD	Maternal-Infantil Vall d´Hebron Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Goya M, Pratcorona L, Merced C, Rodó C, Valle L, Romero A, Juan M, Rodríguez A, Muñoz B, Santacruz B, Bello-Muñoz JC, Llurba E, Higueras T, Cabero L, Carreras E; Pesario Cervical para Evitar Prematuridad (PECEP) Trial Group. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet. 2012 May 12;379(9828):1800-6. doi: 10.1016/S0140-6736(12)60030-0. Epub 2012 Apr 3. Erratum in: Lancet. 2012 May 12;379(9828):1790.

Layout table for additonal information

Responsible Party:	Maria Goya, MD, PhD, PhD, Maternal-Infantil Vall d´Hebron Hospital
ClinicalTrials.gov Identifier:	NCT00706264
Other Study ID Numbers:	PECEP-TRIAL
First Posted:	June 27, 2008 Key Record Dates
Results First Posted:	March 17, 2021
Last Update Posted:	March 17, 2021
Last Verified:	March 2021

Keywords provided by Maria Goya, MD, PhD, Maternal-Infantil Vall d´Hebron Hospital:


Short cervix preterm birth arabin pessary

Additional relevant MeSH terms:

Layout table for MeSH terms

Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications	Silicon Trace Elements Micronutrients Physiological Effects of Drugs

To Top